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Abstract
Dietary therapy represents an important tool in the management of chronic kidney disease (CKD), mainly through a
balanced reduction of protein intake aimed at giving the remnant nephrons in damaged kidneys a “functional rest”.
While dialysis, transplantation, and pharmacological therapies are usually seen as “high tech” medicine, non
pharmacological interventions, including diets, are frequently considered lifestyle-complementary treatments. Diet is one
of the oldest CKD treatments, and it is usually considered a part of “mainstream” management. In this narrative review
we discuss how the lessons of complementary alternative medicines (CAMs) can be useful for the implementation and
study of low-protein diets in CKD. While high tech medicine is mainly prescriptive, prescribing a “good” life-style change
is usually not enough and comprehensive counselling is required; the empathic educational approach, on which CAMs
are mainly, though not exclusively based, may support a successful personalized nutritional intervention.
There is no gold-standard, low-protein diet for all CKD patients: from among a relatively vast choice, the best
compliance is probably obtained by personalization. This approach interferes with the traditional RCT-based
analyses which are grounded upon an assumption of equal preference of treatments (ideally blinded). Whole
system approaches and narrative medicine, that are widely used in the study of CAMs, may offer ways to
integrate EBM and personalised medicine in the search for innovative solutions respecting individualization,
but gaining sound data, such as with partially-randomised patient preference trials.
Background
Chronic kidney disease (CKD): an example of a highly
complex, life-long disease
Dialysis and transplantation are life-long, life-sustaining
treatments requiring multiple drug therapies, and a high
technological level of “mainstream medicine” [1–3].
However, like all life-long, chronic diseases they require
not only integration of complex therapies into everyday
life (multiple drugs in the earlier phases of the diseases,
and then drugs and dialysis or drugs and a kidney
transplant, not necessarily in this order), but also a
change in lifestyle, including diet.
In this regard, CKD treatments merge technology (dialy-
sis, transplantation, multiple drug therapy), which belongs
to/“mainstream medicine”, and lifestyle interventions (ex-
ercise, weight loss, low-protein diets) which are conversely
often considered a part of the holistic approach attributed
to “complementary and alternative medicine” (CAM).
While several comprehensive reviews have addressed
the issue of the efficacy of various therapeutic approaches,
including diet, to date, no reviews have been dedicated to
the relationship between a mainstream and a CAM ap-
proach to low protein diets in CKD patients.
Indeed, nutritional treatments share these two facets:
several recent papers aimed at a vast readership of family
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practitioners which assessed diverse diseases cite the
addition of different foods or the use of specific diets as
part of CAM approaches [4–7].
For at least a century chronic uraemia has been consid-
ered an example of “protein intoxication”. Thus, in the
history of “renal medicine”, diets have been attempted as a
way to correct the metabolic alterations of kidney failure
as much as possible [8, 9]. Indeed, the first systematic
studies on low-protein diets in uraemia patients started
with the observation that a protein-restricted diet was ef-
fective in reducing the symptoms of “uraemic toxicity”
and that it was even able to prolong life [10–12]. This role
of life-prolonging therapies was maintained in western
countries until dialysis became widely available; availability
of dialysis, no more a problem in Europe, is however non
universal on a global scale [12–21]. Reconsidering the
goals and modalities of low-protein diets in progressive
renal diseases and keeping in mind the lessons of CAMs
may offer an interesting outlook in the context of “high-
tech” CKD care [20, 22–24]. At a time in which growing
interest (and business) in CAMs may divert attention
from high-tech medicine, “playing in the two fields” may
also aid the physicians in helping patients find effective
coping strategies.
Chronic kidney disease in the new millennium: why is it
difficult to measure progression?
At the beginning of the new millennium, “renal insuffi-
ciency” was redefined and CKD became an umbrella
term encompassing several affections having variable
evolution rates towards end-stage kidney disease (ESRD)
[25–27]. The staging of CKD underlines the similarities
of all advanced kidney diseases, despite different pro-
gression rates which depend upon race, age and under-
lying nephropathy [25–35].
Therapies aimed at slowing CKD progression have to
deal with high baseline heterogeneity that hinders the
demonstration of their long-term advantages and draw-
backs [30–36]. Even the method that is used to measure
progression rate is a matter of controversy. Furthermore,
differences in the hard outcomes, namely start of dialysis
or death, require trials with long observation times
which are expensive and are often affected by many
confounding factors [28–36].
Several studies have focused on different therapeutic
goals which may partially overlap: these goals include
removing the cause of CKD, treating the metabolic de-
rangements, correcting lifestyle habits that are not ne-
cessarily consequent to CKD but that may potentially
worsen the diseases, and reducing the work-load on the
remnant nephrons [20, 37, 38].
Dietary interventions in general, and low protein diets
in particular may play a role at all these levels by, for ex-
ample, treating obesity, correcting hypophosphataemia,
avoiding processed foods, and most importantly, redu-
cing the work-load on the remnant nephrons.
Furthermore, the outcome measure is non-univocal:
slowing the progression of CKD is not synonymous of
delaying dialysis [20].
Long-term follow-up of either homogeneous popula-
tions with similar baseline progression rates or of very
large cohorts is ideally needed to demonstrate an effect
of dietary interventions (and, indeed, one of the observa-
tions of the famous MDRD study was that it would have
probably given different results over a longer follow-up
[39–41]). The initial GFR decrease, achieved by “renal
rest”, or correction of the relative hyperfiltration may
interfere with short-term analyses [42, 43].
Conversely, delaying dialysis requires attaining stable
metabolic balance that is, at least partly, independent of
GFR. However, the analysis of this short term goal is only
apparently easier since it is deeply entangled with the
pharmacological “mainstream approach” and reflects vari-
ous policies of dialysis start which are not merely based
upon (relatively) simple measures, such as GFR. The new
Canadian guidelines on dialysis start clearly underline that
whenever an “intent to defer” policy is chosen, wise clin-
ical judgement cannot be replaced by formulae [44].
Heterogeneity of diseases, heterogeneity of progression,
and heterogeneity of goals and measures add to the charm,
but also to the complexity of the analysis of dietary
approaches in CKD patients. Without a change in the
approach, the issue will probably remain open forever.
Low-protein diets in CKD: why is the evidence not
evident enough?
Many of the questions posed in the 1986 paper published
in the Lancet entitled: “Dietary treatment for chronic renal
failure, ten unanswered questions” are currently still un-
answered. Among them, some highlight the complexity
and heterogeneity of chronic kidney disease (Does chronic
renal failure always progress?), while others underline the
difficulties in standardization of low protein diets in
clinical practice (When should a low-protein diet start?
Which low-protein diet? How should we assess progres-
sion, nutritional status or compliance?) [45]. However, in
the literature there are several evidence-based demonstra-
tions of the possible role low protein diets may play in
delaying ESRD, including several RCTs and a Cochrane
review [46–58]. Furthermore, we are not aware of any
large studies demonstrating a higher progression rate in
non-malnourished, on-diet patients; in addition, data on
lower costs are concordant [48, 49, 51], and there is no
evidence showing that being on the diet results in any sur-
vival disadvantage after the start of dialysis [51, 59, 60].
The risk of malnutrition is frequently cited, but the
data are at best as inconclusive as those cited by the diet
“advocates” [61–68].
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Low protein diets are however still underutilized [20].
Table 1 summarizes some of the reasons why even
“best quality” evidence is often considered non conclu-
sive or does not affect the clinical management of CKD
patients. Many of these reasons underline how the
prescriptive modality, which is typical of high-tech medi-
cine, may be less suitable than the educational modality,
which is typical of CAMs, for the management of diets
in CKD patients.
The first reason why the treatment with the best cost-
benefit ratio is underutilized in the expensive CKD
scenario may be the difference between the amount of
time it takes to prescribe a drug or define the parameters
of a dialysis treatment (mainly requiring technical skills),
and to recommend lifestyle changes (especially in the
case of diet) which are deeply rooted in personal prefer-
ences and social habits. In this regard, the barriers for
the implementation of LPDs may be the result of the
difficulty in conciliating the prescription and follow-up
of a diet with a classic “mainstream medicine” approach.
Some comments regarding the MDRD study, the largest
randomised controlled study on LPDs in CKD, are in
line with this interpretation: some experts claimed
that MDRD actually demonstrated that prescribing a
diet is not enough, since patients tend to lean to the
dietary habits of their choice [39–43]. Hence, the re-
sults of the “intention to treat” analysis (diet as a
“mainstream prescription”) are negative (no advantage
of an LPD on CKD progression), while the results of
the “per protocol” analysis (diet as an educational inter-
vention) suggest a positive role for LPDs in slowing CKD
progression (Table 1).
The outstanding results obtained in some centres with
a great deal of experience in selecting and following-up
patients on low protein diets have rarely been replicated
in other settings [51–59]. The selection issue is funda-
mental: randomization is felt to be unethical on dialysis:
this is why peritoneal dialysis and hemodialysis have
never been randomised and their results are acknowl-
edged as a matter of prescription and therapeutic adher-
ence. Strangely enough, the same caveats are not applied
to diets. Diet, as well as dialysis, depends upon the pa-
tients’ choices, and the few RCTs that were performed on
dialysis frequency (3 versus 6 dialysis sessions per week)
and those carried out on very low protein diets share
an extremely low enrolment rate (in the 10–30 %
range) [52–54, 59, 69–71]. Accordingly, one of the
main criticisms of the unique Brunori study on diet
versus dialysis is that it enrols about 30 % of the popu-
lation screened for recruitment (and the percentage of
cases randomised in the Garneata trial on very low pro-
tein diets is about 10 %) (Table 1). Such a low preva-
lence demonstrates the presence of a strong patient
preference and suggests that adapting the prescription
to the individual may be more successful than random-
izing therapies. These issues merge with those related
to quality of life, as will be further discussed [72–77].
Diet is not a drug: the “low-protein menu” in CKD
Wikipedia, the world’s largest source of on-line informa-
tion, states “diet is the sum of food consumed by a person
or other organism”; however, in clinical practice, the word
“diet” is often interpreted with a restrictive (or even puni-
tive) connotation, meaning the reduction of at least some
foods [77, 78]. Limiting, reducing, and abolishing, are
probably not the best slogans for a “marketing strategy” to
improve compliance among CKD patients. Indeed, some
authors presently prefer the terms “nutritional treatments”
or “nutritional interventions” to define strategies aimed at
changing dietary habits and not at restricting the use of
some (many-most) foods [77–80].
The concept of low-protein diets is presently undergo-
ing a substantial change, mainly as a consequence of the
changes in the definition of “adequate” protein intake
which has shifted in recent years from 1–1.2 g/Kg/day to
0.8 g/Kg/day, according to the most recent FDA Reference
Daily Intake or Recommended Daily Intake [81, 82]. The
issue of dietary protein content in the overall population
is complex, and is entangled with that of healthy lifestyle;
the rediscovery of traditional and Mediterranean diets,
and the attention to reducing additives and processed
foods are two emerging aspects of this issue [83–90].
A low protein diet is not necessarily a healthy diet;
however, the cultural trend towards reducing proteins
and canned, preserved and processed foods plays in
favour of our patients, for whom the older “moderate”
protein restriction (0.8 g/Kg/day) is now synonymous of
a “biologically normal/adequate” protein intake, and who
may choose a vegan-vegetarian or traditional diet (for
example “Mediterranean”) with a lower risk of being
“discriminated” in a carnivorous world [77].
Table 2 shows the main “menus” of low protein diets
as defined according to; the daily protein intake relative
to body weight, to the main foods, to the room for
personalization and to the type of approach (“main-
stream prescription” versus “CAM education”).
Vegan-vegetarian diets
In the general population, veganism and vegetarianism
are not only diets, they are integrated into a philosophy
of life. This is a setting in which a mainstream approach
(need to reduce proteins) finds a fertile ground in the
growing attention to a “healthy” lifestyle and in a
philosophy of life which ranges from respect for ani-
mals to avoiding diseases [91–95]. Hence, such diets
are often listed along with CAMs in the treatment of
diseases other than CKD. Overall, the protein content
in vegan diets is lower than in omnivorous diets, and
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Table 1 Some comments on the main RCTs con LPDs enrolling at least 50 patients per arm
Study Comparators N and groups Main results Limitations Other comments
Klahr S et al., N
Engl J Med. 1994
(MDRD) [39]
LPD vs No diet;
LPD vs LPD
Study 1, 585 patients: usual diet:
1.3 g/Kg/day LPD: 0.58
Study 2, 255 patients on or vLPD
(plus BP control)
moderate CKD: small benefit LPDs.
severe CKD: no difference in ESRD
progression on LPDs and vLPD
Highly complex study. The results are given
as ITT; however PP analysis shows a significant
effect of LPDs, thus highlighting the role of
compliance.
The largest RCT on LPDs leading to
inconclusive results: it may be also
read as measure of the limitations
of RCTs analysed as ITT, due to
compliance issues
Brunori G, et al.





56 patients in each group
(296 screened)
vLPDs are effective in delaying the
need for dialysis without increasing
mortality
Only about 30 % of the initial population
accepted being randomised. No information
on the follow-up and outcomes of the
excluded patients.
The only study randomizing dialysis
vs vLPDs; highly relevant even if
randomizing such intrusive issues
may be perceived as “unethical”
Cianciaruso B, et al.
Nephrol Dial
Transplant 2008 [57]
0.55 LPD and 0.8
LPD in CKD
stage 4–5
200 patients on 0.55 diet, 192
on 0.8 diet (screened 753; initial
randomization: 423 pts)
LPD at 0.55 g/kg/day guarantees
better metabolic control than a 0.8
diet.
Relatively low compliance in the 0.55 study
group (compliant patients: 27 % in the 0.55-
Group and 53 % in the 0.8-Group), thus
blunting the conclusions. At present 0.8
should be a “normal protein”
Very large study, on two “moderately
restricted LPDs: it shows that even
within the “moderate restriction range”
the lower the better, without risk of
malnutrition
Garneata L et al.
JASN 2016 [59]
vLPD vs LPD in
CKD stages 4–5
vLPD: 104 patients LPD: 103
patients (Screened 1413; non
compliance is the main reason
for non being randomised)
Better correction of metabolic
abnormalities and lower need for
dialysis in the vLPD cohort.
Only 14 % of screened patients were
randomized. Optimal compliance is a
requisite for randomization, indirectly
suggesting that these diets are an option
for relatively few CKD patients.
The largest recent RCT targeted on
supplemented vLPDs vs LPDs.
Underlines the importance of vegan
diet and of supplementation.











Table 2 The “LPD menu”: some reflections on compliance
Type of diet Protein restriction
(g/Kg/bw)
Main features “Best patients” Main advantages Main disadvantages Personalization; main approach
“Traditional” 0.6–0.8 g/Kg/day; mixed
proteins
Modulated upon quantity
of usual food; in moderate
and hot climates, traditional
cuisine is more plant based,







A very natural approach,




attention to quantity and
quality of food
Large room for personalization,
discovery and rediscovery of
traditional cuisine; flexible;
Educational approach is needed.
Vegan 0.6–0.8 g/Kg/day;
vegetable proteins
Unrestricted vegan diets are
usually in the 0.7–0.9 g/Kg/day
protein intake range; due to
the different bioavailability,
a 0.7 diet roughly corresponds







A “trendy” approach, due to
the diffusion of veganism in
the western world; a natural
diet that may have other
favourable effects on health
Demanding: requires special
attention to quality of food
and to the integration of
legumes and cereals. Risk
of B12, vit D and iron deficits
Quite good room for
personalization, especially for not
becoming boring; relatively flexible;
Educational approach is needed.
Vegan supplemented 0.6 g/Kg/day; vegetable
proteins, supplemented
with a mixture of
amino- and keto-acids
Based upon forbidden (animal
origin) and allowed (all other)
food. Animal-derived food is
allowed only in “free meals”
young working
people, who want





need to integrate legumes
and cereals, thus reducing
the risk of nutritional
deficits




are not supplied by the health
care system
Some room for personalization,
especially for not becoming
boring; relatively flexible;
Educational approach has to
be combined with a prescription
approach (supplements)
Protein-free food 0.6 g/Kg/day; mixed
proteins







May allow a reduction
of proteins without
changing eating habits
The protein-free food tastes
different and may not be “tasty”,
it is expensive where foods are
not supplied by the health care
system. The food has to be
prepared separately
Large room for personalization,
may preserve previous habits in
Mediterranean settings; relatively








with a mixture of
amino- and keto-acids;
higher dose as with
the 0.6 diet
Based upon forbidden (animal
origin) and allowed (all other)
food. Animal-derived food is
allowed only in “free meals”











Adding many pills to the usual,
often already demanding drug list.
Very difficult if protein- free food is
not available.
Expensive where supplements and
protein-free foods are not supplied
by the health care system
Scarce room for personalization; not
flexible; Educational approach has
also to be focused on compliance;












it is roughly 0.7 g/Kg/day. However, they are usually
considered together with the “0.6” omnivorous diets on
account of the lower absorption and bioavailability of
vegetable proteins and of their lower effect on renal
filtration [96–105].
Vegan-vegetarian diets are often discussed together
since the distinction between them is relatively new. The
term vegan was coined in 1944 by Donald Watson:
“vegan” from the beginning and end of vegetarian “be-
cause veganism starts with vegetarianism and carries it
through to its logical conclusion”. The two definitions
were often used interchangeably in the past, however,
these diets are different: vegan diets avoid any foods de-
rived from an animal source, including eggs and dairy
products [91–95]. The list of variants is long and includes
various combinations such as ovo-vegetarian (eggs only),
lacto-vegetarian (milk and dairy products), pescetarian or
pesco-vegetarian (fish is allowed). As for vegan diets,
honey is excluded by some, and allowed by others and the
same is true for shellfish. In a world of processed food,
vegans-vegetarians try to avoid all animal-derived compo-
nents, such as sugars that are whitened with bone char,
cheeses that use animal rennet, or gelatine from collagen.
The attitude of “no harm” is extreme in fruitarianism,
which is based upon fruit, nuts, seeds, and food gathered
without “harming the plant” [94, 95, 106].
It is thus clear that, beyond the CKD context, the
differences are not related to “food” but also to the “con-
cept of food” and, more extensively, to the concept of
life [91–95].
It is worth remembering a paper which signalled a
new interest in LPDs in CKD patients which appeared
about 30 years ago in the BMJ. It dealt with CKD in a
group of Buddhist monks as compared with other
subsets of Indian CKD patients. The very low protein
content was indicated, together with the practice of
meditation, as the putative cause of the very low pro-
gression rate in the monk population; at that time, the
fact that Buddhist monks are vegetarians was not men-
tioned [107, 108]. Collaterally, we may also cite that
prayer and meditation are presently considered the most
widespread CAM worldwide [109, 110].
Regardless of the reason for making this choice, be it
medical of personal, the preparation of vegan food is time
consuming and attention must be paid to integrating
different types of cereals, nuts and legumes into each meal
to avoid nutritional deficits; however, provided deficits are
avoided, these diets are safe in all phases of life, including
pregnancy and lactation [111–114].
Supplemented vegan diets
Vegan-vegetarian diets are the basis for further integra-
tion into different schemes: very low protein (or “0.3”)
diets are basically vegan and are supplemented by
protein-free foods to supply energy, and by a mixture of
aminoacids and ketoacids; a “0.6” simplified scheme has
also been developed, with promising results also in eld-
erly, diabetic or pregnant CKD patients [115–124]. Sup-
plements are however “pills”; they may have an additive
effect as scavengers of uraemic toxins, but they have to
be prescribed, hence the educational and prescriptive
approaches are combined. While different combinations
of aminoacids and ketoacids were used in the past, in
Europe two are available and are marketed by the same
Company, the difference being the absence of trypto-
phan in the preparation that is available in Italy. The
dose of the supplements is standardized in the “0.3” diet
(1 pill every 5 Kg of body weight), while in the 0.6 diets
a “compromise dose (1 pill/10 Kg) is chosen in an effort
to find a balance between “too many pills” and the risk
of malnutrition which is intrinsically linked to CKD and
is enhanced by acidosis, depression, and possibly even
by unbalanced diets [116, 125].
The role of supplements is different in “very low” and
“low” protein diets: in the former they are needed to
avoid protein malnutrition while in the latter, the
addition of supplements allows to simplify the dietary
scheme in previously omnivorous patients who are
“forced” into a vegan regimen, or in patients who do not
like protein-rich plant foods, namely legumes.
Omnivorous traditional diets
Hippocrates said that food is the first medicine.
Humankind has quickly shifted in the last century
from relatively low food availability to a higher protein
and energy supply. In many traditional diets, including
Mediterranean diets or the extensively studied Okinawa
diet (from one of the islands with the greatest longevity
in the world), animal-derived food is a sort of “nutri-
tional complement” on the basis of an otherwise vegan
diet [126–134]. As a consequence, moderate protein
restriction may be feasible in the context of several
“traditional diets”. This issue is coming of age in a mo-
ment in which attention is being placed on healthy food
and on consuming food that is processed minimally or
not at all, which is possible only if it is produced in the
surrounding area (i.e., “zero Km” food), thus implicitly
supporting a return to a more traditional cuisine.
Adaptation may be difficult in settings where the
baseline diet is poor in vegetables, fruits, cereals and
legumes; however it should be kept in mind that
animal-derived protein content has only recently risen
in the “rich” world and that most traditional or “poor”
cuisines have a relatively low protein intake [134–137].
Taking into account that CKD is mainly a disease of
the elderly and that the sharp increase in protein in-
take occurred in most of the western world less than
one century ago, designing tailored traditional diets in
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CKD may follow an “historical” educational approach in
which patients are solicited to go back to their childhood
to find adequate or adaptable dietary patterns.
0.6- diets with protein-free food
Protein-free food is an idea that was “made in Italy” and
conceived in an era of limited dialysis availability: “pro-
tein-free pasta” was invented in the sixties in a search
for calorie-rich, protein-poor food [138].
In fact, other natural protein-free, energy-rich foods
(tapioca, butter, sugar, fruits, vegetables) could be com-
bined only in very monotonous diets which were ex-
tremely difficult to follow especially by patients who
were already experiencing the deleterious effects of
uraemia and acidosis on both their appetite and on
gastrointestinal motility. The systematic use of
protein-free food is limited to Italy where these prod-
ucts are available free of charge to CKD patients and
where up to half of the protein intake derives from
bread and pasta (12 g of protein per 100 g). Replacing
these foods allows patients to reach the target protein
intake without making any substantial changes in diet-
ary habits [138–141]. In Italy, these diets are often well
followed by elderly patients while, at least in our ex-
perience, younger patients prefer vegan approaches
[142–145]. A prescription approach focused on con-
suming bread and pasta “from the pharmacy” is usually
enough. Since however they are less palatable than
what people are used to, education, aimed at under-
standing the reasons and goals of the LPD and at
suggesting specific ways of cooking food to improve
taste, represents an important strategy for improving
adherence and coping.
Mainstream, complementary medicine and CKD: where is
the diet?
On Google, the term “mainstream medicine” retrieves
over 3 million results and there are several different
definitions among the first hits. Some of them are
tautological and some are centred on “who” practices
the medicine: “Medicine as practised by holders of
M.D. or D.O. degrees and by their allied health profes-
sionals” [146]. Other definitions focus on the type of
treatment “A system in which medical doctors and
other healthcare professionals (…) treat symptoms and
diseases using drugs, radiation, or surgery” [147].
Others are more complex and include an explanation
of the pathogenesis of the diseases: a general term for
conventional healthcare based on the “western model”
of evidence-based practice for diagnosing and treating
disease. Mainstream medicine assumes that all physio-
logic and pathological phenomena can be explained in
concrete terms, and “best practice” is the final result of
a stream of objective analyses. They begin with non-
human model systems, evolve through blinded studies
and a statistical analysis of the results, finally leading to
guidelines to which doctors should adhere in order to
achieve optimal patient outcomes [148]. In addition,
they also include social elements: “The approach to
healthcare as practised in developed nations is based on
scientific data for diagnosing and treating disease;
mainstream medicine assumes that all physiologic and
pathological phenomena can be explained in concrete
terms; the tools of mainstream medicine include non-
human model systems, blinded studies, and statistical
analysis to ensure reproducible results” [149].
Diet or nutritional approaches are never cited within
these definitions of mainstream medicine. Conversely,
on Medline plus, along with a general definition of
Complementary and alternative medicines, CAM is the
term for medical products and practices that are not
part of standard care. Standard care is what medical
doctors, doctors of osteopathy, and allied health profes-
sionals, such as nurses and physical therapists, practice.
Dietary supplements are cited, while natural products
are in first place in the classification of CAMs in the
National Institute of health website [150, 151].
Diet prescription in mainstream medicine and CAMs
The concept of diet may however be different in main-
stream and complementary medicine: in the first case, it
is usually based upon specific, measurable prescriptions,
while in the second case it is more commonly part of a
lifestyle, often with emphasis on disease prevention [7].
The limits are elusive, and no wonder, therefore, if a
broad search strategy on Medline, combining the terms
“Chronic kidney disease” and “alternative” or “comple-
mentary” or “allied” medicine retrieves, along with pa-
pers on CAMs, several studies on diets which are often
defined as “alternative” to early dialysis, or “complemen-
tary” to pharmacological treatments. Thus, even if diet
in CKD is not strictly considered a CAM, the terms cur-
rently employed for defining CAMs (complementary or
alternative) identify many relevant recent papers on the
dietary treatment of CKD [152–157].
The use of these terms is probably not only a seman-
tic exercise: diet is often cited as an alternative to early
dialysis or as a treatment that is complementary to
ACE-inhibition or to other drug therapy (for instance,
diuretics) [20, 158–161]. In this regard, a critical observa-
tion from the CAM point of view may offer some insights
for a better understanding of the limits of applying “con-
ventional” evidence-based medicine (EBM) analysis to
low-protein diets in CKD, as well as into the possible role
for a “whole system” analysis and for a narrative, personal-
ized approach to maximize compliance (or, perhaps better
stated as “concordance”) to low-protein diets in CKD
patients [162–165].
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Personalised medicine, or RCTs? The lesson of the holistic,
whole system approach
In the era of personalised medicine, we might wonder
whether a randomised controlled trial is the best way to
demonstrate the effects of changes in dietary habits and,
more than this, if it is ethically sound to randomise such
an intrusive lifestyle change [166–169].
In this regard, mainstream medicine should reflect on
the lesson learned from CAMs and the focus might shift
from proving the superiority of a single treatment (diet
vs no diet; moderately- versus severely-restricted diets
etc.) to an observational multidimensional “whole system”
approach [7, 170–177].
A very interesting health technology assessment on
the role of the preferences of professionals and patients
in randomised controlled trials states that “All RCTs in
which participants and/or professionals cannot be
masked to treatment arms should attempt to estimate
the participants’ preferences….” [178]). Current ap-
proaches may not be fit to highlight differences, and
other study designs, in particular the new “partially
randomized patient preference (PRPP) trial model”,
which was developed for the analysis of CAMs, have
already been applied to several fields of mainstream
medicine [179–186].
No study is without pitfalls, and there are sound criti-
cisms to virtually every study design [187]. However, ac-
cording to an educational report in the BMJ: “when the
effectiveness of the intervention depends on the subject’s
active participation (…) a randomised trial may be in-
appropriate because the very act of random allocation
may reduce the effectiveness of the intervention” [173].
If the focus on diets has to shift from issues regarding
effectiveness to those of feasibility, then the implementa-
tion strategy should probably be personalized and should
take into account the features of each patient [142]. This
“narrative” approach may be seen as the other side of
the moon as compared to a randomised trial approach.
However, evidence-based medicine is fully compatible
with narrative, individualized approaches provided that
flexible, comprehensive and innovative study designs
are chosen [188–190]. Paraphrasing a JAMA paper
“Scientific reports (or RCTs) are genuinely dispassion-
ate, characterless, and ahistorical. But their translation
and dissemination (implementation in clinical practice)
should not be” [191]. Dealing with personalized medi-
cine, we should probably learn from patients’ prefer-
ences, and be happy with the fact that a treatment may
have positive results, at least in experienced centres, in
the absence of sound evidence on severe drawbacks
and side effects. In this regard, the lessons learned from
dialysis, which is chosen on the basis of the patients’
preference in the setting of an overall equivalence of
side effects, may be extended to the diet, which is
probably wrongly considered less intrusive in daily life
than the choice of the different types of renal replace-
ment therapy [69–71].
What we did not discuss, but should not forget
Talking about diet, broadly defined on Wikipedia as
“everything we eat”, is extremely complex and no review
of a single issue, such as protein intake, can be exhaust-
ive without touching upon other aspects, such as caloric
intake, vitamins and oligo-elements, additives and con-
taminants. In particular, this is crucial in CKD where the
presence of kidney disease impairs the activation of vita-
min D, leading to a deficient absorption of calcium and
to hyperphosphataemia; low-protein diets are usually de-
ficient in vitamin B12, vitamin D, and iron. Conversely,
hyper-vitaminosis may be a threat, in particular for vita-
min D [192–194]. The toxicity of additive and trace
elements, such as pesticides, has only recently been
studied; negative effects are likely to be enhanced by
reduced renal depuration [194–196]. We know less
about individual elements, such as selenium, which is
important in the oxidative pathway; furthermore, the
network of saturated-unsaturated fatty acids is ex-
tremely complex and only partly known, and bicarbon-
ate supplementation is still an open issue, while the
discussion on all these items is beyond the scope of this
review [197–199]. Again, a flexible holistic approach,
which is more common in CAMs than in mainstream
medicine, may be of interest. Allowing at least one
(and in our experience up to three) free meals per
week may help avoid deficits, generically speaking by
enriching the diet, but the idea that “body wisdom”
can help identify which foods the body needs is ap-
pealing [24, 200]. A holistic approach not only to the
patient, whose diet is an important part of daily life,
but also to the diet as a whole and not only as a “re-
duction of” may reduce the risk of focusing on single
elements, and thus losing sight of the whole problem.
Tips for counselling
There is probably at present no best low-protein diet,
but, in the absence of contraindications, the best ap-
proach is probably to offer the patients a choice of diets
with different options and protein content, bearing in
mind that the most important issue is not the optimal
prescription, but the optimal compliance and target
achievement (Table 2).
In this regard, the prescriptive approach that deals
with low protein diets as it does with drug therapies may
be combined with the educational approach that is typ-
ical of CAMs by integrating dietary habits into daily
life [201–203].
Patients should be aware that there is a high degree of
uncertainty with regard to the choice of their dietary
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treatment and that its aim is to reduce the signs, symp-
toms and complications of renal failure and then to
delay the need for dialysis. Furthermore, even if this is
beyond the scope of this review, they should be warned
that a low-protein diet is not necessarily a healthy diet,
and that several other factors, such as type of renal
disease, type of proteins, salt and phosphate intake,
use of canned and processed food, and effective en-
ergy intake can modulate the risks and the clinical
success [194–196].
Suggestions for research
Long-term interventions that require a profound change
in everyday life are difficult to assess, at least with the
current study strategies. Clinical research needs long-
term observations and long term follow-up, whenever
possible even after the start of dialysis, to check for
carry-over effects and for attrition biases. Since the re-
port and publication biases suggest that only experi-
enced centres with sound, positive data should publish
their series and studies, efforts should be made to build
large multi-centre series involving centres with different
types of experience on low-protein diets. Multi-centre
studies should take into account the important cultural
differences in eating habits and cuisine which are often
present even within the same country. Both “per proto-
col” and “intention to treat” analyses may be relevant in
chronic interventions and both should probably be
analysed [203, 204].
Since it is somewhere between a mainstream prescrip-
tion and a complementary therapy, the study of diet in
chronic kidney disease should merge the suggestions of
both approaches. Integration among various study de-
signs that take into account patients’ preferences (obser-
vational, randomised, partially randomised, etc.) is more
promising than focussing on a single type of analysis, be
it randomised or observational.
Conclusions
There is no ideal low-protein diet for all CKD patients.
However, on the basis of the present evidence which
shows an advantage in terms of dialysis-free follow-up,
and a lack of advantage (or even a disadvantage) in early
dialysis start, all CKD patients should be offered a “good
diet”, or better, an option among various “good diets”
since the best one is the one that is truly followed by
the patient. The methodological flaws and limitations
of the present evidence are probably also linked to
the fact that “traditional” RCTs are based upon an as-
sumption of equal preferences that is not applicable
to low-protein diets.
A diet is not a drug.
Diet integration into daily life is highly dependent
upon preferences and personal choices, and in this
regard, the experience of CAMs may be important for
integrating this potentially precious tool into the life of
our patients, shifting our efforts from standardization to
adaptation, as per the lesson of narrative medicine.
These approaches do not clash with classic, evidence-
based medicine; on the contrary, they need solid EBM
support, integrating the conventional, more rigid study
designs, such as RCTs, with new ones, such as whole-
systems approaches or partially randomised patient
preference trials.
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